Latest in 2024, the targeted drug sotoraxib has become the new favorite of medicine!

Sotorasib is a revolutionary anti-cancer drug and belongs to a new generation of targeted drugs in the field of tumor treatment. Its unique feature is that it targets KRAS gene mutations that are common in tumors. This mutation is extremely common in many types of cancer, but has been difficult to effectively treat in the past.

As an inhibitor of the KRAS G12C mutation, sotoraxib inhibits the abnormal activity of the KRAS protein by targeting this specific mutation, thus inhibiting the growth and division of cancer cells. The originality of this mechanism has attracted widespread attention and expectations in the field of tumor treatment.

Clinical trials have shown that sotoraxib has significant efficacy in the treatment of KRAS G12C mutated non-small cell lung cancer and other tumors. It not only brings about prolonged survival, but also achieves encouraging results in improving patients' quality of life and alleviating symptoms.

The launch of sotoracib provides a glimmer of hope for cancer patients who have long been affected byKRAS gene mutations. This innovative treatment method opens up new treatment avenues for cancer patients and marks a major breakthrough in the field of cancer treatment. With the in-depth research and continuous clinical practice of sotoracib, it is believed that it will become an important pillar of tumor treatment in the future and bring more good news to patients.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.